Business Context and Reporting Period
This Form 8-K Current Report was filed by Dyadic International, Inc. on May 8, 2019, covering events occurring on May 5 and May 6, 2019. The filing details the entry into a material definitive agreement regarding the sub-licensing of the Company's proprietary C1 gene expression platform.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The primary financial consideration disclosed is the compensation structure for the new agreement:
- Up-Front Consideration: Dyadic will receive a 7.5% ownership interest in Alphazyme, LLC upon successful technology transfer.
- Future Consideration: The agreement includes additional milestone payments and a percentage of royalties on net sales incorporating the C1 platform.
- Extension Option: Alphazyme may extend the exclusivity period by 12 months in exchange for an additional 2.5% ownership interest in Alphazyme.
Material Changes
The material change reported is the execution of a Sub-License Agreement with Alphazyme, LLC. This agreement grants Alphazyme rights to commercialize pharmaceutical products using Dyadic's C1 gene expression platform for detecting, measuring, or producing nucleic acid therapeutics or diagnostics. The agreement is subject to the terms of a prior license between Dyadic and Danisco US, Inc. dated December 31, 2015.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The agreement establishes an initial 18-month exclusivity period following technology transfer, after which the license becomes non-exclusive. Dyadic will become a party to the Alphazyme Limited Liability Company Agreement upon receipt of the up-front consideration.
Risks and Contingencies: The receipt of the 7.5% ownership interest is contingent upon the "successful transfer of C1 technology." The filing notes that specific items in the full agreement (Exhibit 10.1) have been redacted.
Investor Verification Checklist
- Verify the status of the technology transfer required to trigger the 7.5% equity payment.
- Review the redacted terms in Exhibit 10.1 to understand specific royalty percentages and milestone definitions.
- Confirm the terms of the underlying license agreement with Danisco US, Inc. (dated Dec 31, 2015) that governs this sub-license.
- Assess the financial impact of the 7.5% equity stake in Alphazyme, LLC, noting that no valuation was provided in this filing.